Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 338 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Comparative Effectiveness Study Clear all

Conditions: Respiratory Distress Syndrome
Interventions: Bubble CPAP- BabiPlus, Respiralogics, Bubble CPAP- B&B Bubbler, B&B Medical devices; Device
Lead sponsor: Marya Strand, MD; Other
Eligibility: 1 Day to 100 Days
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania

Conditions: Venous Leg Ulcers, Diabetic Foot Ulcers
Interventions: PICO System, tNPWT System; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Carlsbad, California • Fresno, California • Martinez, California + 12 more

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Interventions: Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam; Drug
Lead sponsor: Evopoint Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Denver, Colorado • Hartford, Connecticut • Miami, Florida + 7 more

Conditions: Postoperative Hemorrhage
Interventions: Fibrocaps (fibrin sealant), Gelfoam; Device
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pediculosis
Interventions: Spinosad, Permethrin 1%; Drug
Lead sponsor: ParaPRO LLC; Industry
Eligibility: 6 Months and older
Enrollment: 558 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 3 more

Conditions: Postmenopausal Osteoporosis
Interventions: RGB-14-P, Prolia®; Drug
Lead sponsor: Gedeon Richter Plc.; Industry
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Miami, Florida • Miami Lakes, Florida • Decatur, Georgia + 1 more

Conditions: End-stage Renal Disease
Interventions: PROPATEN, Standard Graft; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 5
States / cities: Little Rock, Arkansas • New Orleans, Louisiana • Cleveland, Ohio + 1 more

Conditions: Pre Diabetes, Diabetes
Interventions: Diabetes Prevention Program, Healthy Living Program; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Rochester, New York

Conditions: Screening Colonoscopy
Interventions: colonoscopy; Procedure
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Ulcerative Colitis
Interventions: Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg; Procedure · Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 76
States / cities: Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more

Conditions: Smoking Cessation, Smoking, Nicotine Dependence
Interventions: Varenicline, Nicotine lozenge, Nicotine Patch; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1,086 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Obstructive Sleep Apnea of Adult, Insomnia, Circadian Rhythm Sleep Disorder, Sleep Related Movement Disorders, Narcolepsy and Hypersomnia, Parasomnia
Interventions: CONV care for the diagnosis and treatment of sleep disorders, PCCM for the diagnosis and treatment of sleep disorders; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1,836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Redwood City, California

Conditions: HIV Infections
Interventions: MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).
Interventions: clarithromycin extended-release tablets, clarithromycin immediate-release tablets; Drug
Lead sponsor: Abbott; Industry
Eligibility: 40 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 135
States / cities: Birmingham, Alabama • Columbiana, Alabama • Hoover, Alabama + 122 more

Conditions: Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
Interventions: Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Seattle, Washington

Conditions: Skin Infections, Bacterial
Interventions: Retapamulin Ointment, 1%; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Months to 24 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Tuscaloosa, Alabama • Bentonville, Arkansas • Orange, California + 3 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Nystatin, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Fresno, California • San Francisco, California • Baltimore, Maryland + 2 more

Conditions: HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions: Topotecan; Drug
Lead sponsor: SmithKline Beecham; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 2 more

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 9 more

Conditions: Disk Herniated Lumbar
Interventions: Activity Restriction, Activity as Tolerated; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Ovarian Cancer
Interventions: Docetaxel, Carboplatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 19
States / cities: Fort Myers, Florida • Jupiter, Florida • Orlando, Florida + 16 more

Conditions: Non-ischemic Dilated Cardiomyopathy
Interventions: Autologous hMSCs, Allogeneic hMSCs; Biological
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years to 95 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Comparative Effectiveness Study of Bubble CPAP Devices in the NICU

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Single-Use Negative Pressure Wound Therapy System vs. Traditional Negative Pressure Wound Therapy System (tNPWT)

A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients

Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

U.S. Study of Fibrocaps in Surgical Hemostasis

Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice

Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

Propaten Randomized Investigation on Cost-benefit and Efficacy

Comparing Diabetes Prevention Programs

Comparison of Adenoma Detection Rate Among Water, Carbon Dioxide and Air Methods of Minimal Sedation Colonoscopy

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers

Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis

Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)

Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome

Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

EHR Embedded Comparative Effectiveness Studies--CPS

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)